|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.18 USD | +1.46% |
|
-3.02% | -39.04% |
| Apr. 26 | European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading, End Week Up 3.4% | MT |
| Apr. 17 | Evaxion Announces Phase 2 Clinical Trial Update | CI |
Evaxion Biotech A/S reported earnings results for the full year ended December 31, 2023. For the full year, the company reported sales was USD 0.073 million. Net loss was USD 22.13 million compared to USD 23.17 million a year ago.
Basic loss per share from continuing operations was USD 8.1 compared to USD 9.8 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -39.04% | 21.8M | |
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
EVAXION BIOTECH A/S 
